Navigation Links
BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
Date:8/1/2008

---------

MBP8298 (dirucotide) is a synthetic peptide that consists of 17 amino acids having a sequence identical to that of a portion of human myelin basic protein (MBP). MBP8298 (dirucotide) is being developed for the potential treatment of multiple sclerosis (MS), an autoimmune disease caused by immune attack against normal components of the central nervous system. The sequence of MBP8298 is associated with the autoimmune process in MS patients with certain immune response genes (HLA types DR2 and/or DR4); MS patients having these genes represent 65 to 75 percent of all MS patients.

The apparent mechanism of action of MBP8298 (dirucotide) is the induction or restoration of immunological tolerance with respect to ongoing immune attack as a result of high doses of peptide delivered periodically by the intravenous route. The potential benefit of MBP8298 (dirucotide) for any individual patient is therefore expected to be related to the role this peptide plays in that patient's immune system. The degree of immunomodulation achieved will depend on the relationship among the peptide, HLA molecules and T cells.

The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of Neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types DR2 and/or DR4. Thus, MBP8298 (dirucotide) has the potential to be used as a tailored therapy for patients genetically determined to express the appropriate HLA molecules.

About Multiple Sclerosis

------------------------

Multiple sclerosis (MS) is thought to affect as many as 2.5 million people worldwide, including approximately 75,000 in Canada, 400,000 in the United States and more than 500,000 in Europe. It is a disease that affects more women than men, with onset typically occurring between 20 and 50 year
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... July 07, 2015 , ... ... $107.56 million in 2015, growing at a CAGR of 17.89% between 2015 and ... aptamers, and XNA-based aptamers. Based on applications, the report is segmented into diagnostics, ...
(Date:7/7/2015)... ... July 07, 2015 , ... Currently deployed within several ... developed to solve many of the complex logistical and data management challenges associated ... clinical sites and/or remote data coordination centers. , CentrePoint drastically reduces personnel ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... Polytechnic Institute (WPI), offers new insights into how virulent fungi adapt through genetic ... spread, and how that battle leaves them temporarily weakened. These insights may provide ...
(Date:7/6/2015)... , July 6, 2015  Emdeon ... into a definitive agreement to acquire Altegra ... intervention platforms that combine data aggregation and ... capabilities to achieve actionable insights and improved ... combine Altegra Health,s risk adjustment and quality ...
Breaking Biology Technology:Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 2Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 4Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 5ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 2ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4Emdeon to Acquire Altegra Health 2Emdeon to Acquire Altegra Health 3Emdeon to Acquire Altegra Health 4
... June 17 Berlin Heart Inc. today,announced it has ... FDA,to support the ongoing Investigational Device Exemption (IDE) study ... Almond of,the Children,s Hospital of Boston, and Bob Kroslowitz, ... serve as Co-Principal,Investigators for the grant project "Safety and ...
... , ... More Seed Options in the Marketplace. , ... Des Moines, Iowa, and Atlanta, Ind. (Vocus) June 17, 2009 –- Pioneer ... have entered into research and distribution agreements to bring additional corn and soybean products to ...
... N.C., June 17 Campbell Alliance, the leading management ... today announced that it has appointed industry veterans Jon ... Both gentlemen will work directly with John Campbell, ... areas to advise the firm,s emerging and midsize client ...
Cached Biology Technology:Berlin Heart Inc. Receives FDA Orphan Product Development Grant 2Pioneer Hi-Bred and Beck's Hybrids Enter into Research and Distribution Agreements 2Pioneer Hi-Bred and Beck's Hybrids Enter into Research and Distribution Agreements 3Campbell Alliance Adds Industry Veterans Jon W. McGarity and David Lilley as Executive Vice Presidents 2Campbell Alliance Adds Industry Veterans Jon W. McGarity and David Lilley as Executive Vice Presidents 3Campbell Alliance Adds Industry Veterans Jon W. McGarity and David Lilley as Executive Vice Presidents 4
(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
(Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
(Date:6/18/2015)... , June 18, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces that its ... segment on "Money on the Mark", scheduled to air on ... June 20 th . The broadcast ... from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO Gino ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... strongly predisposes carriers to develop cancer at an early ... researchers today at the American Association for Cancer Research ... person should have two normal copies of the powerful ... as Li-Fraumeni syndrome (LFS), one defective copy of p53 ...
... Curcumin, the yellowish component of turmeric that gives curry ... anti-cancer properties. Researchers from Tohoku University in Sendai, ... two molecular analogues of curcumin that demonstrate even greater ... the first test of these molecules in a mouse ...
... international team of scientists today announced the results of ... lung cancer, the worlds leading cause of cancer deaths. ... the journal Nature, the research provides a comprehensive view ... revealing more than 50 genomic regions that are frequently ...
Cached Biology News:Rare cancer-causing syndrome found, for the first time, in Singapore 2Curry-derived molecules might be too spicy for colorectal cancers 2Genome study charts genetic landscape of lung cancer 2Genome study charts genetic landscape of lung cancer 3
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
... immunoblotting the antibody reacts against the reduced ... MMP-2 or MMP-2 bound to TIMP-2. affinity ... Solution in 0.01 M phosphate buffered ... 15 mM sodium azide. synthetic peptide corresponding ...
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
... its effects by binding ... a disulfide-linked heterotetrameric protein ... subunits and two Beta ... following configuration: Beta-Alpha-Alpha-Beta. ...
Biology Products: